Runze Wang

Runze Wang

Auto-generated profile, based on publicly available information

Runze Wang

School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RWRunze Wang
Runze Wang
QZQiuyu Zhang
Qiuyu Zhang
YLYi Lin
Yi Lin
YHYangpei Huang
Yangpei Huang
YYYuanfei Yang
Yuanfei Yang
SWShuangshuang Wan
Shuangshuang Wan

6 May 2026 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
RWRunze Wang
Runze Wang
CWChaoqiao Wang
Chaoqiao Wang
BHBinjin Hu
Binjin Hu
QZQiuyu Zhang
Qiuyu Zhang
JXJixin Xu
Jixin Xu
SWShuangshuang Wan
Shuangshuang Wan

25 November 2025 in Communications Biology
Verified
Journal Article
Open access
SWShuangshuang Wan
Shuangshuang Wan
YLYu Lei
Yu Lei
YJYue Jin
Yue Jin
RWRunze Wang
Runze Wang
MZMeng Zhang
Meng Zhang
DJDazhi Jin
Dazhi Jin
The incidence of Clostridioides difficile infection (CDI) has been rising globally in recent years. Treating CDI is complicated by antibiotic-induced disruption of the normal gut microbiota, which promotes CDI recurrence and increases the risk of therapeutic failure. We used an AI-assisted approach to screen small molecule inhibitors targeting the receptor binding domain of toxin B (TcdB). Biliverdin (BV) had strong binding affinities with all TcdB variants. In vitro results showed that BV exhibited no cytotoxic effects on cells and didn’t affect growth of C. difficile , yet markedly suppressed cytotoxic effects induced by TcdB1-4. Encapsulating BV in intestinal epithelial cell-derived extracellular vesicles (I-EVs) significantly recovered body weight, enhanced survival rate, reduced TcdB load, and alleviated intestinal lesions in treated gerbils. Notably, BV treatment not only restored the abundance of gut microbiota but also significantly increased the quantity of gut-beneficial Firmicutes . BV also exerted its anti-CDI effect by restoring the short-chain fatty acid metabolic network. Our findings indicate that BV shows promise as a natural small-molecule therapeutic that attenuates broad-spectrum TcdB-induced injuries, highlighting its potential for clinical translation in CDI treatment.